INTRODUCTION. Knee osteoarthrosis (KO) among the adult population often leads to permanent disability, a sharp decrease in the quality of life, and chronic use of analgesics. At the same time, according to the clinical guidelines of the Russian Rheumatology Association for osteoarthrosis treatment, hyaluronic acid medications are included in the list recommended for KO, and they are particularly effective at stages I-II of the disease. AIM. Evaluation of the efficiency of the dietary supplement B-Luron for KO patients within 12 weeks therapy. MATERIAL AND METHODS. A total of 70 patients with stage I-II deforming osteoarthrosis (DOA) were followed up, consecutively included in the study from December 14, 2021 to January 31, 2022, for an average of 90 days (3 months). RESULTS AND DISCUSSION. The efficiency of B-Luron for I-II DOA stages was shown: a statistically significant decrease in the level of pain in knee joints, an improvement in the function of the joint were found compared to the initial state. The analysis of objective data showed a positive trend in ultrasound parameters and MRI features of joint inflammation and a decrease in the need for analgesics within 12 weeks. CONCLUSION. In a prospective randomized clinical trial with 70 knee DOA patients as a part of the combination therapy (12 weeks use) with non-steroidal anti-inflammatory drugs, B-Luron showed its efficiency for stages I-II of the disease; there was a positive trend in ultrasound parameters and MRI signs of inflammation in the joints as well as a decrease in the need for non-steroidal anti-inflammatory drug use.
arthrosis of the knee joint, osteoarthritis, B-Luron, hyaluronic acid preparations, analgesics, quality of life
1. Kellgren J.H., Lawrence J.S. Radiological assessment of osteo-arthrosis. Annals of the Rheumatic Diseases. 1957; 16(4): 494-502. https://doi.org/10.1136/ard.16.4.494
2. Korzh N.A., Bolhovitin P.V. Diagnosticheskie kriterii rannego osteoartroza kolennogo sustava. Istonchik: http://health-ua.com/arti-cle/6728-diagnosticheskie-kriterii-rannego-osteoartroza-kolennogo-sustava (data obrascheniya 06.12.2022)
3. Klinicheskie kriterii OA kolennyh sustavov. Dostupno na: https://www.invalidnost.com/index/osteoartroz/0-204 (data obrascheniya 06.12.2022)
4. Interpretaciya pokazateley IMT (v sootvetstvii s rekomendaciyami VOZ): Dostupno na: https://medicalc.ru/indeksmassytela (data obrascheniya 06.12.2022)
5. Hondroitina sul'fat. RLS. Dostupno na: https://www.rlsnet.ru/active-substance/xondroitina-sulfat-985 (data obrascheniya 06.12.2022)
6. Gialuronovaya kilota. RLS. Dostupno na: https://www.rlsnet.ru/active-substance/gialuronovaya-kislota-2858 (data obrascheniya 06.12.2022)
7. Vitamin E. RLS. Dostupno na: https://www.rlsnet.ru/drugs/vitamin-e-alfa-tokoferola-acetat-69221#dejstvuyushhee-veshhestvo (data obrascheniya 06.12.2022)
8. Magnitskaya N.E., Ryazancev M.S., Maysigov M.N., Logvinov A.N., Zaripov A.R., Korolev A.V. Perevod, validaciya i kul'turnaya adaptaciya ortopedicheskogo oprosnika IKDC 2000 subjective knee form dlya ocenki sostoyaniya kolennogo sustava. Geniy ortopedii. 2019; 25(3): 348-354. https://doi.org/10.18019/1028-4427-2019-25-3-348-354
9. Kopylova D.A., Ostapenko V.A. Svyaz' klinicheskih proyavleniy osteoartroza s izmeneniem urovnya interleykina 6 v krovi. Nauchno-prakticheskaya revmatologiya. 2012; 54(5): 34-36
10. EQ-5D: Oprosnik po zdorov'yu. Versiya na russkom yazyke dlya Rossii. Dostupno na: https://spb.hse.ru/data/2020/03/10/1563014698/EQ-5D-3L.pdf (data obrascheniya 06.12.2022)
11. Briggs A.M., Woolf A.D., Dreinhöfer K., Homb N., Hoy D.G., Kopansky-Giles D., Åkesson K., March L. Reducing the global burden of musculoskeletal conditions. Bulletin of the World Health Organization. 2018; 96(5): 366-368. https://doi.org/10.2471/BLT.17.204891
12. Cross M., Smith E., Hoy D., Nolte S., Ackerman I., Fransen M., Bridgett L., Williams S., Guillemin F., Hill C.L., Laslett L.L., Jones G., Cicuttini F., Osborne R., Vos T., Buchbinder R., Woolf A., March L. The global burden of hip and knee osteoarthritis: estimates from the global burden of disease 2010 study. Annals of the Rheumatic Diseases. 2014; 73(7): 1323-1330. https://doi.org/10.1136/annrheumdis-2013-204763
13. Obesity and overweight. Key facts. World Health Organization, 2018. Available at: https://www.who.int/news-room/fact-sheets/detail/obesi-ty-and-overweight (accessed 06.12.2022).
14. Perruccio A.V., Yip C., Badley E.M., Power J.D. Musculoskeletal Disorders: A Neglected Group at Public Health and Epidemiology Meetings? American Journal of Public Health. 2017; 107(10): 1584-1585. https://doi.org/10.2105/AJPH.2017.303990
15. Postler A., Ramos A.L., Goronzy J., Gunther K.P., Lange T., Schmitt J., Zink A., Hoffmann F. Prevalence and treatment of hip and knee osteoarthritis in people aged 60 years or older in Germany: an analysis based on health insurance claims data. Clinical Interventions in Aging. 2018; (13): 2339-2349. https://doi.org/10.2147/CIA.S174741
16. The Bone and Joint Decade. Global Alliance for Musculoskeletal Health. Key facts from The Global Burden of Disease 2012. Available at: http://bjdonline.org/?page_id=1574 (accessed 12.01.2022).
17. Ul'yanov V.Yu., Kalyuta T.Yu., Romakina N.A., Yurkovec A.A. Nauchnyy otchet po klinicheskomu issledovaniyu «odnocentrovoe randomizirovannoe placebo-kontroliruemoe dvoynoe slepoe issledovanie dlya ocenki effektivnosti, bezopasnosti i perenosimosti biologicheski aktivnoy dobavki «Bi-Luron» u pacientov s osteoartrozom kolennyh sustavov. Saratov. 2022: 68 s.
